John S. Markowitz, Pharm.D., BCPP

John S. Markowitz


Pharmacotherapy and Translational Research



PHONE: (352) 273-6262

CV: Link to CV



  • Pharm.D., University of Tennessee College of Pharmacy
  • B.S. in Biology, with a concentration in microbiology, Memphis State University

Biographical Sketch

Dr. Markowitz has been credentialed by the Board of Pharmaceutical Specialties in Psychiatric Pharmacy since 1997. Following his training, Dr. Markowitz served for a number of years as a hospital-based Clinical Specialist in Psychiatry within the Institute of Psychiatry at the Medical University of South Carolina (MUSC) in Charleston, South Carolina. He eventually entered into a primary faculty research position in the MUSC College of Pharmacy’s Department of Pharmaceutical & Biomedical Sciences with a dual appointment in the Department of Psychiatry and Behavioral Sciences where he had remained prior to joining UF in 2009.


  • American Society of Hospital Pharmacists
  • American Society of Clinical Pharmacology and Therapeutics
  • American College of Clinical Pharmacy
  • College of Psychiatric and Neurologic Pharmacists

Research Interests

  • Dr. Markowitz’s research program has encompassed both in vitro and in vivo investigations including normal volunteer pharmacokinetic studies directed at the assessment of drug-drug interactions in psychopharmacology, botanical-drug interactions, as well as their associated clinical effects. More recently, the research program has focused on variability in drug metabolism, disposition, and therapeutic response as a consequence of genetic variability which influences both drug transporters and hepatic enzymes. He has received research support from both the pharmaceutical industry and the National Institutes of Health.

Selected Publications

Zhu H-J, Langaee TY, Gong Y,  Wang X, Pepine CJ, Cooper-DeHoff RM, Johnson JA,  Markowitz JS. CES1P1 variant −816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. Eur J Clin Pharmacol  2016;72:681-687.

Wang X, Zhu H-J, Munoz J, Gurley BJ, Markowitz JS. An ex vivo approach to botanical-drug interactions: A proof of concept study. J Ethnopharmacol 2015;163:149-156. (PMID: 25623616)

Kawaguchi-Suzuki M, Frye RF, Zhu H-J, Brinda BJ, Chavin KD, Bernstein HJ, Markowitz JS. The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metab Dispos 2014;42:1611-1616 (PMID: 25028567)

Zhu HJ, Wang X, Gawronski B, Brinda B, Angiolillo D, Markowitz JS. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 2013;344:665-672. (PMID: 23275066)

Zhu H-J, Brinda B, Froehlich TE, Markowitz JS. A discriminative genotypic method for detecting CES1A1 and CES1A2/CES1A3 genetic variants. Pharmacogenetics & Genomics   2012; 22:215-8. (PMID: 22237548)

Zhu HJ, Appel DI, Gründemann D, Markowitz JS. Interaction of organic cation  transporter 3 (SLC22A3) and amphetamine. J Neurochemistry 2010;114:142–9. (PMID: 20402963)

Zhu H-J, Patrick KS, Yuan H-J, Wang J-S, Donovan JL, DeVane, CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: Clinical significance and molecular basis. Am J Hum Genetics 2008;82:1241-48. (PMID: 18485328)

Full Publication List via PubMed RSS feed